Thermo Fisher Scientific completed its acquisition of Olink Holding in July 2024 in a transaction that values Olink at approximately $3.1 billion. The acquisition gives Thermo Fisher access to Olink's proprietary Proximity Extension Assay (PEA) technology, which offers high-throughput protein analysis with a library of more than 5300 validated protein biomarker targets.
Cyborg Score Rationale
Olink is a market-leading proteomics platform now backed by Thermo Fisher Scientific (July 2024). The company has established proprietary technology (PEA) with extensive biomarker coverage, serving major biopharmaceutical and academic institutions. However, as an acquired subsidiary, independent public trading has ended.
Top Insights
Proprietary PEA technology with 5,300+ validated protein biomarker targets provides significant competitive moat in proteomics
Acquired by Thermo Fisher (July 2024, $3.1B valuation) now operates as integrated subsidiary with expanded market reach and resources
Platform serves major pharma companies and leading academic institutions for drug discovery, diagnostics, and precision medicine applications
Integration into Thermo Fisher's Life Sciences Solutions leverages complementary mass spectrometry and genomics capabilities
Named Competitors
Molecular Devices — Cellular analysis and protein detection systems
Abzena — Biologics development and protein analytics
Creative Proteomics — Proteomics research services and solutions
Recent Developments
(July 2024) Thermo Fisher Scientific completed acquisition of Olink for approximately $3.1 billion
(June 2026) Launched neurodegeneration research webinar series on biomarker precision and protein analysis
Open the full interactive Olink Holding AB (publ) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.